The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results.
 
Nick Pavlakis
Honoraria - Bayer; BeiGene; Gene Solutions; Illumina; Merck KGaA; MSD Oncology; Pierre Fabre; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Duo Oncology; Gilead Sciences; Johnson & Johnson/Janssen; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; Zymeworks
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
Sumitra Ananda
No Relationships to Disclose
 
Howard Chan
No Relationships to Disclose
 
Marion Harris
No Relationships to Disclose
 
Warren Joubert
No Relationships to Disclose
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
Research Funding - Boryung Pharmaceuticals; Samyang
 
Choong-kun Lee
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Roche; SERVIER
Speakers' Bureau - Boryung Pharmaceuticals; Celgene/Bristol-Myers Squibb; Handok; Novartis; Sanofi
Research Funding - Boryung Pharmaceuticals (Inst); GC Biopharma (Inst); Lunit (Inst); Ono Pharmaceutical (Inst)
 
WooJin Lee
No Relationships to Disclose
 
Lara Lipton
No Relationships to Disclose
 
Adnan Nagrial
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Do Youn Oh
No Relationships to Disclose
 
Joon Oh Park
Consulting or Advisory Role - ABL Bio; Adicet Bio; Arcus Biosciences; AstraZeneca; Celgene; ImmuneOncia; Intocell; MediRama; Merck Serono; SERVIER
Research Funding - Celgene; medpacto; SERVIER
Travel, Accommodations, Expenses - Minneamrita Therapeutics
 
Terrie-Anne Cock
Employment - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Patents, Royalties, Other Intellectual Property - Amplia Therapeutics
Travel, Accommodations, Expenses - Amplia Therapeutics
 
Sarah Kinkel
Employment - Amplia Therapeutics
 
Nicole Kruger
Consulting or Advisory Role - Amplia Therapeutics
Travel, Accommodations, Expenses - Amplia Therapeutics
 
Chris Burns
Employment - Amplia Therapeutics
Leadership - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Honoraria - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Amplia Therapeutics
Travel, Accommodations, Expenses - Amplia Therapeutics
 
Jason Lickliter
Employment - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Travel, Accommodations, Expenses - Amplia Therapeutics